APLLTD
Alembic Pharma
Alembic Pharma (APLLTD) Stock Analysis & Case Study
Is APLLTD a good buy? The data-driven verdict.
Alembic Pharma (APLLTD) trades at ₹781,on the numbers it worth a closer look, a Downstox Snapshot Score of 57/100.
On the numbers, Alembic Pharma (APLLTD) worth a closer look, a Downstox Snapshot Score of 57/100, weighing fairly valued at 21.1× earnings, ROE of 13.4%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
APLLTD fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is APLLTD overvalued? APLLTD P/E vs its sector
APLLTD's P/E of 21.1× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 1.41% dividend yield is below the peer median of 1.65%.
The bull case for APLLTD
- A 21.1× P/E sits in the fair-value band, neither cheap nor stretched.
- A healthy 13.4% return on equity.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
APLLTD Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. APLLTD scores 4/9,mixed financial health.
APLLTD MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy APLLTD with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 30.2% | 3.3× |
| DhanCHEAPEST | 30.2% | 3.3× |
Compare every broker on the APLLTD MTF page.
APLLTD vs peers,sector comparison
About Alembic Pharma: sector, index & market-cap context
Alembic Pharma (APLLTD) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹15,373 Cr. See more Nifty 200 stocks.
How the APLLTD Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Alembic Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
APLLTD analysis, FAQs
Is Alembic Pharma (APLLTD) a good buy?
On the numbers, Alembic Pharma (APLLTD) worth a closer look, a Downstox Snapshot Score of 57/100, weighing fairly valued at 21.1× earnings, ROE of 13.4%. This is a data snapshot for research, not investment advice.
Is APLLTD overvalued or undervalued?
APLLTD trades at 21.1× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the bull case for APLLTD?
A 21.1× P/E sits in the fair-value band, neither cheap nor stretched. A healthy 13.4% return on equity.
What are the risks in APLLTD?
No model or past record guarantees future returns, treat this as one input, not a decision.